Skip to content
Menu

Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsUpgradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.

Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.

Read at benzinga.com